X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Fulford India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs FULFORD INDIA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA FULFORD INDIA ASTRAZENECA PHARMA/
FULFORD INDIA
 
P/E (TTM) x 93.7 398.8 23.5% View Chart
P/BV x 13.3 6.2 214.6% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 ASTRAZENECA PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
FULFORD INDIA
Mar-14
ASTRAZENECA PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs1,285942 136.4%   
Low Rs634450 140.9%   
Sales per share (Unadj.) Rs189.6691.4 27.4%  
Earnings per share (Unadj.) Rs-0.211.5 -1.8%  
Cash flow per share (Unadj.) Rs3.815.4 25.0%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs68.6380.0 18.1%  
Shares outstanding (eoy) m25.003.90 641.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.11.0 502.7%   
Avg P/E ratio x-4,712.760.7 -7,760.7%  
P/CF ratio (eoy) x249.645.3 550.8%  
Price / Book Value ratio x14.01.8 763.2%  
Dividend payout %017.4 0.0%   
Avg Mkt Cap Rs m23,9882,714 883.7%   
No. of employees `0001.60.4 351.1%   
Total wages/salary Rs m1,605505 317.7%   
Avg. sales/employee Rs Th3,040.26,073.0 50.1%   
Avg. wages/employee Rs Th1,029.21,137.4 90.5%   
Avg. net profit/employee Rs Th-3.3100.7 -3.2%   
INCOME DATA
Net Sales Rs m4,7402,696 175.8%  
Other income Rs m92125 73.4%   
Total revenues Rs m4,8322,822 171.2%   
Gross profit Rs m-130-46 279.7%  
Depreciation Rs m10115 665.8%   
Interest Rs m010 0.0%   
Profit before tax Rs m-13954 -255.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m510 53.0%   
Profit after tax Rs m-545 -11.4%  
Gross profit margin %-2.7-1.7 159.1%  
Effective tax rate %-3.717.7 -20.7%   
Net profit margin %-0.11.7 -6.5%  
BALANCE SHEET DATA
Current assets Rs m2,7261,738 156.8%   
Current liabilities Rs m2,435545 447.0%   
Net working cap to sales %6.144.3 13.9%  
Current ratio x1.13.2 35.1%  
Inventory Days Days7448 152.2%  
Debtors Days Days414 946.9%  
Net fixed assets Rs m1,03512 8,700.0%   
Share capital Rs m5039 128.2%   
"Free" reserves Rs m9421,443 65.3%   
Net worth Rs m1,7161,482 115.8%   
Long term debt Rs m00-   
Total assets Rs m4,1562,077 200.1%  
Interest coverage xNM6.7-  
Debt to equity ratio x00-  
Sales to assets ratio x1.11.3 87.8%   
Return on assets %-0.12.6 -4.7%  
Return on equity %-0.33.0 -9.8%  
Return on capital %04.3 0.0%  
Exports to sales %5.70-   
Imports to sales %6.524.5 26.4%   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306659 46.5%   
Fx inflow Rs m37517 2,177.9%   
Fx outflow Rs m470673 69.8%   
Net fx Rs m-96-656 14.6%   
CASH FLOW
From Operations Rs m-890 -9.0%  
From Investments Rs m-146105 -139.3%  
From Financial Activity Rs m862-14 -6,114.9%  
Net Cashflow Rs m709181 392.5%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 0.3 3.8 7.9%  
FIIs % 15.7 0.1 15,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 21.2 42.9%  
Shareholders   12,856 4,783 268.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   DISHMAN PHARMA  GLENMARK PHARMA  SUN PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS